Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Therapeutic Focus
  5. Sensory Organs

Sensory Organs

Evaluate

Thumbnail
May 31, 2023

Go or no go? Key FDA decisions for Argenx and Regeneron

Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.

Thumbnail
May 25, 2023

Archer misses the target

Annexon’s failure in geographic atrophy could clear the way for its rivals.

Article image
Vantage logo
May 02, 2023

Astellas doesn’t buy Apellis

In purchasing Iveric for $5.9bn the Japanese group has plumped for the cheaper geographic atrophy player.

Article image
Vantage logo
April 19, 2023

Viridian aims to prove itself in thyroid eye

Forthcoming data will see the group take on Horizon, but subcutaneous projects could pose the real threat.

Article image
Vantage logo
April 11, 2023

A wider Horizon beckons in thyroid eye disease

Article image
Vantage logo
March 01, 2023

US FDA approval tracker: February 2023

Article image
Vantage logo
January 30, 2023

Go or no go? Overcoming delays

US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.

Article image
Vantage logo
December 12, 2022

Amgen strikes out for the Horizon

Amgen sees off Sanofi and J&J to clinch the rare disease player for $28bn, ensuring that the M&A year ends with a bang.

Article image
Vantage logo
November 30, 2022

Is a big deal on the Horizon?

Article image
Vantage logo
November 08, 2022

Makeover sees Viatris move further away from generics

The speciality group will soon be without biosimilars; in the meantime it's buying two companies with patent-protected medicines.

Article image
Vantage logo
November 04, 2022

Apellis delay raises eyebrows, but Iveric cannot celebrate yet

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up